DIRECTED IMMUNE POWER Trademark

Trademark Overview

On Friday, July 6, 2018, a trademark application was filed for DIRECTED IMMUNE POWER with the United States Patent and Trademark Office. The USPTO has given the DIRECTED IMMUNE POWER trademark a serial number of 88028350. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 29, 2021. This trademark is owned by Torque Therapeutics, Inc.. The DIRECTED IMMUNE POWER trademark is filed in the Treatment & Processing of Materials Services category with the following description:

Manufacturing services for others in the fields of pharmaceuticals and medicine, namely, manufacturing of biotherapeutics, immunotherapeutics, immunomodulators, immunostimulants, immunogenics, antibodies, cell therapeutics, cells, immune cells, and T-cells
directed immune power

General Information

Serial Number88028350
Word MarkDIRECTED IMMUNE POWER
Filing DateFriday, July 6, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 29, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 25, 2019

Trademark Statements

Disclaimer with Predetermined Text"IMMUNE"
Goods and ServicesManufacturing services for others in the fields of pharmaceuticals and medicine, namely, manufacturing of biotherapeutics, immunotherapeutics, immunomodulators, immunostimulants, immunogenics, antibodies, cell therapeutics, cells, immune cells, and T-cells

Classification Information

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateThursday, July 12, 2018
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTorque Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139
Party NameTorque Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Monday, March 29, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 29, 2021ABANDONMENT - NO USE STATEMENT FILED
Saturday, August 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 20, 2020EXTENSION 2 GRANTED
Thursday, August 20, 2020EXTENSION 2 FILED
Thursday, August 20, 2020TEAS EXTENSION RECEIVED
Saturday, February 29, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 20, 2020EXTENSION 1 GRANTED
Thursday, February 20, 2020EXTENSION 1 FILED
Thursday, February 20, 2020TEAS EXTENSION RECEIVED
Thursday, February 20, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 20, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 20, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, August 20, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 25, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 25, 2019PUBLISHED FOR OPPOSITION
Wednesday, June 5, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, May 23, 2019ASSIGNED TO LIE
Thursday, May 9, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, May 2, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 1, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 1, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, January 25, 2019APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, January 25, 2019TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, November 2, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, November 2, 2018NON-FINAL ACTION E-MAILED
Friday, November 2, 2018NON-FINAL ACTION WRITTEN
Thursday, October 25, 2018ASSIGNED TO EXAMINER
Thursday, July 12, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, July 10, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

power immune directed cells manufacturing immunogenics antibodies immunostimulants cell therapeutics immunomodulators immunotherapeutics